AIDS Research Progress Stymied By Narrow Focus, Critics Charge

Critics Charge Author: FRANKLIN HOKE, pp.1 Date: July 11,1994 Disputing what they see as unproductive preoccupation with HIV-specific studies, they step up campaign for a `wider window' of research Progress in AIDS research has faltered in the United States since the mid-1980s, according to some scientists, owing to a premature narrowing of the research focus by the scientific and administrative leadership of the National Inst

Written byFranklin Hoke
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Critics Charge Author: FRANKLIN HOKE, pp.1
Date: July 11,1994

Disputing what they see as unproductive preoccupation with HIV-specific studies, they step up campaign for a `wider window' of research

Progress in AIDS research has faltered in the United States since the mid-1980s, according to some scientists, owing to a premature narrowing of the research focus by the scientific and administrative leadership of the National Institutes of Health, the agency that controls the bulk of funding for AIDS investigations.

With the epidemic well into its second decade and no effective drugs or vaccines yet in sight, these critics contend, the time has come for NIH to broaden its research support beyond the HIV-specific studies currently dominating the research portfolio.

Only through insights gained from new basic investigations in immunology, virology, and other areas largely excluded from NIH AIDS-related funding will the virus and its pathogenic mechanisms be sufficiently well understood to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies